10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin)

Recombinant Antibody
Catalog # APR10096

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P32970
Reactivity	Human
Clonality	ADC
Isotype	IgG1
Calculated MW	21118

Additional Information


Target/Specificity	TNFSF7 / CD27L / CD70
Endotoxin Conjugation	MMAF
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.


Protein Information

Name	CD70 (HGNC:11937)
Function	Expressed at the plasma membrane of B cells, it is the ligand of the CD27 receptor which is specifically expressed at the surface of T cells (PubMed:28011863, PubMed:28011864, PubMed:8387892). The CD70- CD27 signaling pathway mediates antigen-specific T cell activation and expansion which in turn provides immune surveillance of B cells (PubMed:28011863, PubMed:28011864).
Cellular Location	Cell membrane; Single-pass type II membrane protein


Images

The purity of Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) is 99.29%, determined by SEC-HPLC.






The drug-to-antibody ratio (DAR) of the Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) is 3.8.



Immobilized humanCD70-His at 2 ug/mL (30 μL/well) can bind Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) with the EC50 of 0.007612 ug/mL.



Human TNFSF7 / CD27L / CD70 CHO-K1 Cell Line were stained with Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS,The EC50 is 0.11 μg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.